Jpmorgan Chase & CO Exelixis, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,323,859 shares of EXEL stock, worth $115 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,323,859
Previous 7,741,589
31.23%
Holding current value
$115 Million
Previous $186 Million
31.98%
% of portfolio
0.01%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding EXEL
# of Institutions
459Shares Held
246MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$757 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$668 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$579 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$328 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$284 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $6.98B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...